Consequences of HPV-Related Disparities in Head and Neck Cancer

Share this content:
A review article highlighted the racial disparities in head and neck cancer incidence and identified how this relates to HPV infection.
A review article highlighted the racial disparities in head and neck cancer incidence and identified how this relates to HPV infection.

A recent review article highlighted the disparity in the incidence of head and neck cancers between African Americans and whites, as well as identified a potential explanation for this disparity as it relates to human papillomavirus (HPV) infection. The review article was published online January 5, 2019 in the Journal of the National Cancer Institute.

Several disparities exist in head and neck cancer that affect prognosis. Overall, African American patients typically have worse prognoses than white patients, and this is often linked to socioeconomic status and type of health care insurance coverage.

Furthermore, site of origin for head and neck cancers and prevalence rates for certain somatic mutations vary between African American patients and white patients. For instance, African American patients had a lower incidence of oral cavity cancer than white patients (33.8% vs 23.4%, respectively) and higher prevalence of EGFR, KRAS, HRAS, and TP53 mutations than white patients.

In regard to HPV infection, African Americans have lower rates of HPV infection than whites and this, the review authors wrote, is “one of the primary reasons for high mortality and low response to chemo-radiation therapy” among African Americans. HPV infection is linked to certain malignancies, including oral, pharynx, nasal, or larynx squamous cell carcinoma, and these cancer types are less likely to occur in African American patients.

“Although accumulating evidence supports SES [socioeconomic status] and sexual lifestyle preference as the primary determinant of differential HPV infection and overall prognosis of AA [African American] and white patients,” the study authors wrote, “it is worth mentioning that the inherent somatic variations and the HPV-driven intratumoral immune-metabolic phenotype of these races are not exclusive phenomenon but interdependent crucial contributors in the disparity.”


  1. Chaudhary S, Ganguly K, Muniyan S, et al. Immunometabolic alterations by HPV infection: New dimensions to head and neck cancer disparity [published online January 5, 2019]. J Natl Cancer Inst. doi: 10.1093/jnci/djy207

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs